Connect with us

Hi, what are you looking for?

Diagnostics

Manus Receives FDA Breakthrough Designation For NMP Device

Manus Neurodynamica, which develops and markets products and technologies for neuromotor assessment, has been granted Breakthrough Designation by the U.S. Food and Drug Administration (FDA) for its NeuroMotor Pen (NMP) device.

Manus Receives FDA Breakthrough Designation For NMP Device

Breakthrough Designation has been granted for the proposed indication of using the NeuroMotor Pen to support healthcare providers (HCPs) in differentiating between Parkinsonian and non-Parkinsonian tremors in adult patients who are suspected to have Parkinson’s Disease (PD) but have not been diagnosed by other means.

The FDA Breakthrough Device programme is intended to accelerate regulatory approval and help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or debilitating diseases and conditions. This Breakthrough Designation represents a major step towards the technology’s approval in the US market.

Differentiating between a Parkinsonian tremor and other tremor disorders is challenging. Early and correct differential diagnosis is crucial to quickly provide access to best medical treatments and other forms of support. In a community-based study of the accuracy of PD diagnosis, essential tremor (ET), the most common movement disorder, accounted for 48% of the misdiagnoses.

The widespread lack of tremor measurement equipment in the clinic with the ability to detect very subtle tremors is a significant part of the cause for not being able to differentiate between PD and ET.

The NeuroMotor Pen is a unique scalable digital solution for the differential diagnosis of ET and PD that combines sensor technologies, built into a digital pen, with software and an analytical engine with Decision Support System. The interface enables users to record movements non-invasively and analyse parameters of minute limb and hand motion, quantifying fine motor skill. These quantified parameters are used as ‘digital biomarkers’ to provide objective information about movement abnormalities, enabling the accurate differentiation between ET, PD and other tremor disorders.

Once registered in the US, the NeuroMotor Pen will be the only device for PD with clinical claims for differential diagnostic decision making. The Company will now agree a study protocol with the FDA in anticipation of a successful US-based clinical trial demonstrating a similarly high specificity and sensitivity in differential diagnostic decision making, as was achieved in European trials.

The prevalence of PD and ET are at least 1.7 and 7 million respectively in the US, and the current annual cost of treatment for PD in the United States is currently estimated at $14.4 billion. As the population ages and life expectancy increases, the number of individuals in the US with PD is projected to double in the coming generation, representing a very substantial existing and growing market for Manus’ NMP technology.

Dr Rutger Zietsma, CEO of Manus, said: “I am delighted that we have been granted Breakthrough Designation for the NeuroMotor Pen to aid in the differential diagnosis of complex forms of Parkinson’s Disease, which is a large and growing cause of long-term illness and disability in the US and the rest of the world.

“Obtaining Breakthrough Designation represents an important milestone in our path to providing a more effective diagnosis for this irreversibly debilitating disease to improve the lives of this underserved patient population. We look forward to building on this achievement by utilising the Breakthrough Devices Programme to facilitate our pursuit of U.S. regulatory clearance for differential diagnosis of Parkinson’s in close collaboration with the FDA.”

Prof Richard Walker, Northumbria NHS Foundation Trust, professor of ageing at Newcastle University, added: “There is great potential for this device in helping us to assess movement and tremor in older people who may have Parkinson’s or other conditions. It can help with making a diagnosis and also with assessing response to treatment.”

Photo Credit: Manus Neuro

Seen on Med-Tech Innovation News: Article Link

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

Exclusives

IoT is transforming healthcare through wearables, SaMD, and AI. MedTech needs strong branding for the efficiency and cost savings this will provide.

Digital Health

The lack of standardization is a huge problem in the diagnosis and tracking of neurological disorders: because they are so complex and often slow...

FDA

System creates 3D models of the heart with unprecedented anatomical details, allowing physicians to better plan and personalize therapeutic interventions

FDA

Linear Health Sciences has received U.S. FDA clearance and Health Canada approval of its Orchid SRV, a tension-activated breakaway safety release valve designed to reduce the...

You May Also Like

Exclusives

Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm. Innovators across the HealthTech...

Exclusives

PRIA clients are provided a high-touch, white-glove service to support their patient access services.

Exclusives

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Exclusives

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.